We have released exciting new coverage of the stem cell industry. Check it out and let me know what you think?
Early Results in Cynata’s UK Trial of iPSC-Derived MSC Therapeutic Product
Cynata Therapeutics has released exciting early results from its ongoing clinical trial in the UK utilizing an iPS cell-derived mesenchymal stem cell (MSC) therapeutic product, CYP-001. Cynata reports that patients in Cohort A responded very well to CYP-001, with no treatment-related serious adverse events or safety concerns. It is notable that 100% of participants showed a measurable and meaningful improvement in GvHD grade (severity). On January 24th, 2018, the company dosed the first patient in Cohort B, which will receive twice (2x) the dose of patients in Cohort A.
Global Radiation Threats Require Cutting-Edge Counter-Measures
The hematologic component of acute radiation syndrome (ARS) results from damage to the bone marrow and is characterized by acute decreases in red and white blood cell and platelet counts, which can lead to infection, hemorrhage and death. Pluristem’s cell therapy product, PLX-R18, has demonstrated improvement in the recovery of white blood cell, red blood cell, and platelet levels in animals exposed to high levels of radiation. In times of global threats, the free world is looking for a solution, and PLX-R18’s properties make it a potentially ground-breaking treatment.
Applied StemCell Inc. (ASC) is a fast growing biotechnology company that offers an optimized series of tools for basic research study, drug discovery, bio-processing, bio-production and preclinical applications. In this interview with Dr. Ruby Yanru Chen-Tsai, CSO and Co-founder of ASC, we discuss Dr. Chen-Tsai’s impressive background, ASC’s unique product portfolio, its TARGATT™ gene editing technology, and the company’s future trajectory.
What is a RMAT Designation and Who Has One?
As described in Section 3033 of the 21st Century Cures Act, a drug is eligible for regenerative medicine advanced therapy (RMAT) designation if it is a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product, except for those regulated solely under Section 361. In 2017, twelve products were awarded RMAT designation for a variety of indications.
The Perinatal Stem Cell Society Congress is the world's premier conference exploring clinical directions for perinatal stem cells. Dr. Ramon Coronado will speak about exosomes from perinatal tissues, Dr. Robert Hariri will discuss stem cells and longevity, and Dr. Ornella Parolini will present on the immunomodulation of amniotic cells and their derivatives. More than 20 other experts will also present. Use the code “BIOI” to get $100 off your registration and let me know if I will see you there?
Explosion of Interest in Exosome Technologies and Companies Leading the Charge
Although long overlooked, exosomes are rapidly gaining momentum as a novel strategy for accessing the therapeutic effects of stem cells without the risks and difficulties of administering the cells to patients. Exosomes also have enormous potential for use as biomarkers in non-invasive tests, vehicles for drug delivery, and active agents in cosmeceutical products. On the venture capital front, exosomes are receiving funding support with accelerating velocity.
The Making of a Stem Cell Super-Ecosystem with Bernard Siegel
In this interview with Bernard Siegel, Executive Director of the Regenerative Medicine Foundation and Founder of the World Stem Cell Summit (WSCS), we explore his background, changes within the regenerative medicine sector, the importance of industry collaboration, and future directions for stem cell medicine. It is a timely interview, because the WSCS 2018 and Phacilitate's Cell and Gene Therapy World were held as a massive co-located event last week in Miami.
The Market for Stem Cell Exosomes
This 134-page global strategic report reveals trend rate data for exosome patents, grants, scientific publications, and clinical trials, as well as social analytics from Google Trends and Google Adwords. It explores the growing demand for exosome therapeutics, diagnostics, research tools, consumer care products, and manufacturing processes. It identifies the five market segments forming the industry, reveals the market player competing in each niche, presents market size determinations with 5-year projections, and identifies opportunities for commercializing exosome products.
Complete 2017-18 Global Cord Blood Banking Industry Report
This 265-page global strategic report reveals key benchmarks to track and why you should care. Benchmarks are critical to assess, because the cord blood banking industry has matured substantially over the past few years, creating both serious threats and novel opportunities. The industry is maturing and consolidating, with holding companies emerging worldwide. Cord blood banks are diversifying into stem cell biobanks and pairing storage services with other types of prenatal and maternal health products. Technologies for ex vivo expansion of cord blood are also showing promise in numerous clinical trials worldwide.
Global Regenerative Medicine Industry Database 2018 (Final Hours for 50% Off)
This database features 600+ regenerative medicine (RM) companies worldwide, including companies involved with cell and gene therapies, tissue engineering and biomaterials, 3D bioprinting, exosomes, and more. These are companies developing regenerative medicine products for therapeutic use in humans. Act fast to access this searchable, sortable database of all regenerative medicine companies worldwide for 50% off.
Be Great,
Cade President/CEO of BioInformant.com "1st and Only Market Research Firm to Specialize in the Stem Cell Industry"
|
|
|
